Search
ivacaftor/lumacaftor (Orkambi)
Indications:
- treatment of cystic fibrosis with 2 sopies of the CFTR mutation F508del (phenylalanine 508 mutation)*
* most common mutation in cystic fibrosis
Dosage:
- lumacaftor 200 mg/ivacaftor 125 mg
- 2 pills every 12 hours
Adverse effects:
- shortness of breath
- upper respiratory tract infection
- nausea
- diarrhea
- rash
- menorrhagia
Mechanism of action:
- CFTR potentiator
General
pharmacologic combination
pulmonary agent
References
- FDA News Release. July 2, 2015
FDA approves new treatment for cystic fibrosis
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm
Components
ivacaftor
lumacaftor